Top Markets
Coin of the day
Lisata Therapeutics, Inc. Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc.

LSTA
Kedudukan dalam Saham #32451
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on... Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Harga Saham
$1.11
Modal Pasaran
$10.06M
Perubahan (1 hari)
1.38%
Perubahan (1 tahun)
-56.32%
Negara
US
Perdagangan Lisata Therapeutics, Inc. (LSTA)

Kategori

EPS untuk Lisata Therapeutics, Inc. (LSTA)
EPS setakat 2026 TTM: 0
Menurut laporan kewangan terkini dan harga saham Lisata Therapeutics, Inc., EPS semasa syarikat (TTM) adalah 0. Pada akhir tahun 2026, syarikat mempunyai EPS sebanyak 0 sama dengan EPS tahun 2026 iaitu 0.
Sejarah EPS untuk Lisata Therapeutics, Inc. dari 2026 hingga 2026
EPS pada akhir setiap tahun
Tahun EPS Ubah
Tidak cukup data untuk tarikh yang disediakan.
EPS untuk syarikat atau pesaing yang serupa
Syarikat EPS Perbezaan EPS Negara
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE